ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies

被引:35
作者
Kita, Y
Tseng, J
Horan, T
Wen, J
Philo, J
Chang, D
Ratzkin, B
Pacifici, R
Brankow, D
Hu, S
Luo, Y
Wen, DZ
Arakawa, T
Nicolson, M
机构
[1] AMGEN INC,AMGEN CTR,DEPT PROT CHEM,THOUSAND OAKS,CA 91320
[2] AMGEN INC,AMGEN CTR,DEPT MOL BIOL,THOUSAND OAKS,CA 91320
[3] AMGEN INC,AMGEN CTR,DEPT MAMMALIAN CELL MOL BIOL,THOUSAND OAKS,CA 91320
关键词
D O I
10.1006/bbrc.1996.1311
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A panel of mAbs were generated against the purified soluble form of erbB2/Her2 receptor, corresponding to the extracellular region of the receptor, and examined for their ability to mimic the receptor ligand. Some of the mAbs strongly induced tyrosine phosphorylation of 180-185 kDa proteins, including not only Her2 but also Her3 and Her4 receptors, when they were expressed on the surface of breast cancer cells. These mAbs do not cross-react with Her3 or Her4 as demonstrated by competition study. Receptor phosphorylation was also observed with the cell lines transfected with Her2 or a chimeric receptor consisting of the extracellular domain of Her2 and the transmembrane and cytoplasmic domains of epidermal growth factor receptor. Selected mAbs were tested for their ability to change cell morphology, and one specific mAb, mAb74, induced cell morphology changes and apoptosis. (C) 1996 Academic Press, Inc.
引用
收藏
页码:59 / 69
页数:11
相关论文
共 36 条
[1]  
CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303
[2]   CHARACTERIZATION OF A NEU/C-ERBB-2 PROTEIN-SPECIFIC ACTIVATING FACTOR [J].
DOBASHI, K ;
DAVIS, JG ;
MIKAMI, Y ;
FREEMAN, JK ;
HAMURO, J ;
GREENE, MI .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8582-8586
[3]  
DREBIN JA, 1988, ONCOGENE, V2, P387
[4]   ARIA, A PROTEIN THAT STIMULATES ACETYLCHOLINE-RECEPTOR SYNTHESIS, IS A MEMBER OF THE NEU LIGAND FAMILY [J].
FALLS, DL ;
ROSEN, KM ;
CORFAS, G ;
LANE, WS ;
FISCHBACH, GD .
CELL, 1993, 72 (05) :801-815
[5]  
FENDLY BM, 1989, MOL CELL BIOL, V9, P1165
[6]   C-ERBB-2 PROTEIN OVEREXPRESSION IN BREAST-CANCER IS A RISK FACTOR IN PATIENTS WITH INVOLVED AND UNINVOLVED LYMPH-NODES [J].
GULLICK, WJ ;
LOVE, SB ;
WRIGHT, C ;
BARNES, DM ;
GUSTERSON, B ;
HARRIS, AL ;
ALTMAN, DG .
BRITISH JOURNAL OF CANCER, 1991, 63 (03) :434-438
[7]  
HARTMANN LC, 1994, CANCER, V74, P2956, DOI 10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO
[8]  
2-V
[9]   MONOCLONAL-ANTIBODIES DIRECTED TO THE ERBB-2 RECEPTOR INHIBIT IN-VIVO TUMOR-CELL GROWTH [J].
HARWERTH, IM ;
WELS, W ;
SCHLEGEL, J ;
MULLER, M ;
HYNES, NE .
BRITISH JOURNAL OF CANCER, 1993, 68 (06) :1140-1145
[10]   IDENTIFICATION OF HEREGULIN, A SPECIFIC ACTIVATOR OF P185ERBB2 [J].
HOLMES, WE ;
SLIWKOWSKI, MX ;
AKITA, RW ;
HENZEL, WJ ;
LEE, J ;
PARK, JW ;
YANSURA, D ;
ABADI, N ;
RAAB, H ;
LEWIS, GD ;
SHEPARD, HM ;
KUANG, WJ ;
WOOD, WI ;
GOEDDEL, DV ;
VANDLEN, RL .
SCIENCE, 1992, 256 (5060) :1205-1210